Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tyrosine-protein kinase Lck (LCK) is a non-receptor tyrosine kinase belonging to the Src family kinases (SFKs). It is primarily expressed in T lymphocytes and plays a crucial role in T-cell development, activation, and function. Lck initiates T-cell receptor (TCR) signaling by phosphorylating immunoreceptor tyrosine-based activation motifs (ITAMs) on TCR-associated chains. It is also involved in other signaling pathways and cellular processes beyond the immune system, including cell cycle control, adhesion, and neuronal function. Altered LCK function is associated with immunodeficiency disorders, cancer, and autoimmune diseases, making it a potential therapeutic target.
Lck phosphorylates ITAMs on TCR-associated chains, initiating T-cell signaling. Inhibitors of Lck can block this phosphorylation and downstream signaling events.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tyrosine-protein kinase Lck (LCK).